Clinical relevance of KRAS and GNAS Mutationen in cell-free DNA and circulating epithelial cells regarding the development of pancreatic cancer in IPMN patients

Clinical relevance of KRAS and GNAS Mutationen in cell-free DNA and circulating epithelial cells regarding the development of pancreatic cancer in IPMN patients - IPMN

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023356

Enrollment

100

Registered

2021-03-26

Start date

2020-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D13.6

Interventions

Group 1: Observational study: All IPMN patient receive treatment in accordance with guidelines depending on their clinical presentation - conservatively for side duct IPMN, operatively for main duct I

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: IPMN diagnosis; written consent

Exclusion criteria

Exclusion criteria: no written consent

Design outcomes

Primary

Measure	Time frame
Establishment of a liquid biopsy protocol to achieve a detailed molecular characterisation of IPMN and allow risk stratification of malignancy.	—

Secondary

Measure	Time frame
We aim to analyse blood samples from 50 konservatively and 50 operatively treated IPMN patients and correlate the results of circulating epithelial cells and cell-free DNA with existing KRAS and GNAS mutations and the risk of malignancy.	—

Countries

Germany

Contacts

Public ContactChristine Nitschke

Klinik für Allgemein-, Viszeral- und ThoraxchirurgieUniversitätsklinikum Hamburg-Eppendorf

c.nitschke@uke.de040 7410 0

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026